143 related articles for article (PubMed ID: 33442658)
1.
Jaraj D; Höijer J; Widman L; Ahlgren J; Arnesson LG; Einbeigi Z; Klintman M; Vikhe Patil E; Sund M; Fredriksson I; Bergh J; Andreas P
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442658
[TBL] [Abstract][Full Text] [Related]
2. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
3. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
4. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
5. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
6. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
8. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
Abdulkarim BS; Cuartero J; Hanson J; Deschênes J; Lesniak D; Sabri S
J Clin Oncol; 2011 Jul; 29(21):2852-8. PubMed ID: 21670451
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
13. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study.
Hassing CMS; Mejdahl MK; Lænkholm AV; Kroman N; Knoop AS; Tvedskov THF
Breast Cancer Res Treat; 2023 Feb; 198(1):103-112. PubMed ID: 36576678
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
16. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
17. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.
Gnerlich JL; Deshpande AD; Jeffe DB; Sweet A; White N; Margenthaler JA
J Am Coll Surg; 2009 Mar; 208(3):341-7. PubMed ID: 19317994
[TBL] [Abstract][Full Text] [Related]
18. No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.
Frisk G; Ekberg S; Lidbrink E; Eloranta S; Sund M; Fredriksson I; Lambe M; Smedby KE
Breast Cancer Res; 2018 Nov; 20(1):142. PubMed ID: 30458873
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
20. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
